OmeCare

Cardiac DNA Insight®

Personal Genetic Report

Cardiac DNA Insight® does not provide a medical plan or diagnosis.
Before stopping or starting a medication, consult with your physician.

Protected Health Information

CARDIAC DNA INSIGHT®

Protected Health Information

PERSONAL DETAILS	
NAME	Sample Patient
DOB	Jan 1, 1980
SEX	F
ETHNICITY	Caucasian

ORDERING HEALTHCARE PROFESSIONAL

Jess Savala M.D.

LABORATORY INFO	
ACTIVATION CODE	YAHAN-VKCJI
SPECIMEN TYPE	BUCCAL SWAB
COLLECTED DATE	Mar 20, 2020
RECEIVED DATE	Mar 25, 2020
REPORT DATE	Apr 12, 2020

Test Results Reviewed & Approved by:
Laboratory Director,
Jess Savala Jr. M.D.

Cardiovascular Health

PHENOTYPE	OUTCOME
ApoE, type III hyperlipoproteinemia and CVD risk	TYPICAL RISK
Genetic risk for decreased folate	OPTIMIZE INTAKE
Genetic risk for decreased HDL cholesterol	ABOVE AVERAGE RISK
Genetic risk for elevated LDL cholesterol	ABOVE AVERAGE RISK
Genetic risk for elevated triglycerides	AVERAGE RISK
Sickle cell anemia	NOT A CARRIER

Heart Disease / Atrial Fibrillation

PHENOTYPE	OUTCOME
Atrial fibrillation	ABOVE AVERAGE RISK
Beta-blockers, LVEF response	ENHANCED BENEFIT
Caffeine metabolism	FAST METABOLIZER
Coronary artery disease	AVERAGE RISK
Myocardial infarction	AVERAGE RISK
Simvastatin-induced myopathy	TYPICAL RISK
Verapamil and QTc interval	TYPICAL RISK OF PROLONGATION

Hypertension

PHENOTYPE	OUTCOME
Beta-blockers	TYPICAL THERAPEUTIC BENEFIT
Hypertension	AVERAGE RISK
Metoprolol metabolism	EXTENSIVE METABOLIZER
Perindopril	LIKELY RESPONDER
Verapamil vs. atenolol	INCREASED BENEFIT ON VERAPAMIL

Peripheral Arterial Disease / Venous Thrombosis

PHENOTYPE	OUTCOME
Clopidogrel metabolism	EXTENSIVE METABOLIZER
Estrogen supplementation	TYPICAL RISK OF VENOUS THROMBOSIS
Peripheral arterial disease	ABOVE AVERAGE RISK
Venous thrombosis	TYPICAL RISK
Warfarin	TYPICAL SENSITIVITY

Cardiovascular Health

Health Conditions

APOE, TYPE III HYPERLIPOPROTEINEMIA AND CVD RISK

INCREASED RISK

TYPICAL RISK

Genetic Result - APOE ε3/ε3

Gene Tested - APOE

Clinical Implications:

- Patient does not have the APOE genotype associated with increased risk of type III hyperlipoproteinemia, a condition that may lead to severe atherosclerosis and increased risk of cardiovascular disease. Type III hyperlipoproteinemia is characterized by an accumulation of very low-density lipoprotein (VLDL) and chylomicron remnants (known collectively as β-VLDL) in the blood that leads to significantly elevated cholesterol and triglyceride levels.
- Additional genetic factors and environmental factors such as diabetes, obesity, low estrogen levels, or hypothyroidism are thought to contribute to development of the disorder.

Recommendation:

- Routine screening for blood cholesterol levels should be performed at appropriate ages, as recommended by the U.S. Preventive Services Task Force and other groups.

Nutrition

GENETIC RISK FOR DECREASED FOLATE

OPTIMIZE INTAKE

STAY BALANCED

Gene Tested - MTHFR

Clinical Implications:

- Patient's genotype is associated with higher genetic risk for decreased plasma levels of folate and increased plasma levels of homocysteine, a substance linked to risk of cardiovascular disease at high levels.
- Folate can lower levels of homocysteine, and diets rich in folate have been associated with reduced risk of cardiovascular disease. The vitamin is particularly important early in pregnancy for preventing some birth defects.

Recommendation:

- The recommended daily intake for most adults is 400 micrograms. Pregnant women are advised to elevate their daily intake to 600 micrograms.
- Consider advising the patient to increase intake of folate-rich foods.

Metabolic Health Factors

GENETIC RISK FOR DECREASED HDL CHOLESTEROL

HIGH RISK
ABOVE AVERAGE RISK
AVERAGE RISK
BELOW AVERAGE RISK
LOW RISK

Genes Tested - ABCA1, ANGPTL4, CETP, FADS1, GALNT2, HNF4A, KCTD10, LCAT, LIPC, LIPG, LPL, PLTP, TTC39B, ZNF259

Clinical Implications:

- Patient has above average genetic risk of decreased HDL cholesterol levels (below 40 mg/dl).
- The genetic variants contained in this test account for approximately 9.3% of the variance in HDL cholesterol levels.

Recommendation:

- Routine screening for blood cholesterol levels should be performed at appropriate ages, as recommended by the U.S. Preventive Services Task Force and other groups.
- Consider advising the patient to increase physical activity, eat foods rich in omega-3 fatty acids, maintain a healthy weight and avoid smoking.

Metabolic Health Factors

GENETIC RISK FOR ELEVATED LDL CHOLESTEROL

HIGH RISK
ABOVE AVERAGE RISK
AVERAGE RISK
BELOW AVERAGE RISK
LOW RISK

Genes Tested - ABCG8, APOB, CELSR2, HMGCR, HNF1A, intergenic, LDLR, MAFB, NCAN, PCSK9

Clinical Implications:

- Patient has above average genetic risk for borderline-high levels of LDL cholesterol (above 130 mg/dl).
- The genetic variants contained in this test account for approximately 7.7% of the variance in levels of LDL cholesterol.

Recommendation:

- Routine screening for blood cholesterol levels should be performed at appropriate ages, as recommended by the U.S. Preventive Services Task Force and other groups.
- Consider advising the patient to avoid processed foods and foods high in trans fat that contribute to elevated LDL levels. Patient could also be advised to eat a more plant-based diet, foods high in soluble fiber and foods rich in omega-3 fatty acids.
- Consider advising the patient to increase physical activity, maintain a healthy weight and avoid smoking.

Metabolic Health Factors

GENETIC RISK FOR ELEVATED TRIGLYCERIDES

HIGH RISK
ABOVE AVERAGE RISK
AVERAGE RISK
BELOW AVERAGE RISK
LOW RISK

Genes Tested - ANGPTL3, APOB, FADS1, GCKR, LPL, MLXIPL, NCAN, PLTP, TRIB1, XKR6, ZNF259

Clinical Implications:

- Patient has average genetic risk of elevated triglyceride levels.
- The genetic variants contained in this test account for approximately 7.4% of the variance in triglyceride levels.

Recommendation:

- Although the patient's genetic risk of elevated triglycerides is average, it is still important to address diet and lifestyle factors that affect triglyceride levels. For example, a diet high in trans fats, smoking and lack of physical activity may contribute to elevated triglyceride levels.

Carrier Status ✓ **SICKLE CELL ANEMIA**

HOMOZYGOTE
CARRIER
NOT A CARRIER

Gene Tested - HBB

Clinical Implications:

- Patient does not carry the HbS mutation responsible for sickle cell anemia.

Heart Disease / Atrial Fibrillation

Health Conditions ✓ **ATRIAL FIBRILLATION**

INCREASED RISK
ABOVE AVERAGE RISK
AVERAGE RISK

Gene Tested - PITX2

Clinical Implications:

- Patient has above average genetic risk of atrial fibrillation.
- This test outcome was determined using genetic laboratory results in conjunction with the patient's self-reported ethnicity.

Recommendation:

- Depending on personal and family health history, a screening or prevention program and patient education that encourages regular exercise and limiting alcohol and tobacco consumption may be appropriate.

Pharmacogenetics ✓ **BETA-BLOCKERS, LVEF RESPONSE**

ENHANCED BENEFIT
BENEFICIAL

Gene Tested - ADRB1

Clinical Implications:

- Patient's genotype is associated with enhanced benefit in left ventricular ejection fraction (LVEF) following beta-blocker therapy in heart failure patients.
- This result is based on studies of heart failure patients and may not apply to patients being treated for other conditions.
- This genetic effect is not consistent in all studies and influence of this variant on beta-blocker response in other indications, such as atrial fibrillation or hypertension, is uncertain.
- See "Condition-Specific Limitations" in the "Risks and Limitations" section of this report for more information.

Recommendation:

- Use as directed. The most recent drug label should be consulted for up-to-date guidelines and limitations.

Pharmacogenetics

CAFFEINE METABOLISM

FAST METABOLIZER

SLOW METABOLIZER

Genetic Result - CYP1A2 *1F/*1F

Gene Tested - CYP1A2

Clinical Implications:

- Patient's genotype is associated with a rapid rate of caffeine metabolism.
- Patient does not have the CYP1A2 allele (C allele at rs762551) that is associated with increased risk of myocardial infarction when consuming high amounts of caffeine (four or more 8-ounce cups of coffee daily).
- In addition to genetics, caffeine metabolism depends on lifestyle factors, such as amount of coffee consumed, smoking and hormonal birth control.
- This result may not apply to Asians, as the rs762551 marker has not been observed to be associated with caffeine metabolism in Asians.

Recommendation:

- Consider reminding the patient that many beverages that contain caffeine, such as soda, coffee and energy drinks, may also contribute to excess sugar and calorie intake.

Health Conditions

CORONARY ARTERY DISEASE

INCREASED RISK

ABOVE AVERAGE RISK

AVERAGE RISK

Genes Tested - CDH13, HNF1A, Intergenic_10q11, Intergenic_1q41, Intergenic_2q36, Intergenic_5q21, Intergenic_8p22, Intergenic_9p21, MRAS, MTHFD1L, SEZ6L, SMAD3

Clinical Implications:

- Patient has average genetic risk of coronary artery disease.
- This test outcome was determined using genetic laboratory results in conjunction with the patient's self-reported ethnicity.

Recommendation:

- General preventive measures, such as weight loss, regular exercise, or healthy eating, should be encouraged.

Health Conditions

MYOCARDIAL INFARCTION

INCREASED RISK

ABOVE AVERAGE RISK

AVERAGE RISK

Genes Tested - CXCL12, Intergenic_1p13, Intergenic_21q22, Intergenic_9p21, MIA3, OR13G1, PCSK9, PHACTR1, PRR4, SH2B3, WDR12

Clinical Implications:

- Patient has average genetic risk of myocardial infarction.
- This test outcome was determined using genetic laboratory results in conjunction with the patient's self-reported ethnicity.
- Fifteen to twenty percent of individuals who experience myocardial infarction lack conventional risk factors.

Recommendation:

- Patient education regarding the importance of maintaining a healthy weight, regular physical activity and a low-sodium diet with lots of fruits and vegetables could be considered.

Pharmacogenetics

SIMVASTATIN-INDUCED MYOPATHY

INCREASED RISK

TYPICAL RISK

Gene Tested - SLCO1B1

Clinical Implications:

- Patient has typical risk of myopathy if treated with simvastatin.
- While this patient's genetic likelihood of developing simvastatin-induced myopathy is significantly lower than those who have the risk variant, many other factors involved in simvastatin-induced myopathy are still unknown.

Recommendation:

- The most recent simvastatin label should be consulted for updated prescribing information regarding simvastatin dosing limitations and drug-drug interactions.

Pharmacogenetics

VERAPAMIL AND QTC INTERVAL

INCREASED RISK OF PROLONGATION

TYPICAL RISK OF PROLONGATION

Gene Tested - NOS1AP

Clinical Implications:

- Patient's genotype is associated with typical risk of verapamil-induced QTc interval prolongation.
- QTc interval length depends on many factors, including age, gender, other genes, other medications and specific disease pathologies.
- See "Condition-Specific Limitations" in the "Risks and Limitations" section of this report for more information.

Recommendation:

- Use as directed. The most recent drug label should be consulted for up-to-date guidelines and limitations.

Hypertension

Pharmacogenetics

BETA-BLOCKERS

REDUCED THERAPEUTIC BENEFIT

TYPICAL THERAPEUTIC BENEFIT

Gene Tested - GRK5

Clinical Implications:

- Patient's genotype is associated with a typical survival benefit on beta-blockers and, therefore, the patient may have a typical response to beta-blocker therapy.
- This result is based on a study of heart failure patients and may not apply to patients being treated for other conditions. Additionally, this genetic effect was found in African-American patients, and it is not known if patients of non-African ancestry are similarly affected.
- Response to beta-blockers also varies with age, gender, medical history and coprescribed medication.

Recommendation:

- Use as directed. The most recent drug label should be consulted for up-to-date guidelines and limitations.

Health Conditions

HYPERTENSION

INCREASED RISK
ABOVE AVERAGE RISK
AVERAGE RISK

Genes Tested - BCAT1, PPARGC1A

Clinical Implications:

- Patient has average genetic risk of hypertension.
- This test outcome was determined using genetic laboratory results in conjunction with the patient's self-reported ethnicity.
- Over 90% of individuals who develop hypertension are considered to have essential or primary hypertension, meaning that no underlying medical cause can be identified.

Recommendation:

- The U.S. Preventive Services Task Force recommends screening for high blood pressure in adults ages 18 and older.

Pharmacogenetics

METOPROLOL METABOLISM

EXTENSIVE METABOLIZER
INTERMEDIATE METABOLIZER
POOR METABOLIZER

Genetic Result - CYP2D6 *1/*6

Gene Tested - CYP2D6

Clinical Implications:

- Patient's genotype is associated with typical blood pressure and heart rate responses to metoprolol.
- Patient's genotype is also associated with normal CYP2D6 enzyme activity and typical plasma concentrations of metoprolol.
- A small percentage of patients with this genotype may metabolize metoprolol at higher than normal rates and, thus, may not achieve optimal plasma concentrations at standard doses.
- CYP2D6 genotype and metabolizer status may also affect responses to other drugs.

Recommendation:

- The most recent drug label should be consulted for up-to-date dosing guidelines and limitations.
- The drug label warns that CYP2D6 inhibitors are likely to increase metoprolol plasma concentrations and decrease cardioselectivity of metoprolol.

Pharmacogenetics

PERINDOPRIL

LIKELY NON-RESPONDER
LIKELY RESPONDER

Genes Tested - AGTR1, BDKRB1

Clinical Implications:

- Patient's genotype is associated with a typical benefit from standard doses of ACE inhibitors, such as perindopril.
- In one study, stable coronary artery disease patients with this genotype had a 33% reduction in risk of cardiovascular death, non-fatal myocardial infarction or resuscitated cardiac arrest with ACE inhibitor treatment. Perindopril was used to generate the observed effect but other ACE inhibitors might also result in a similar effect.
- This result may not apply to patients who do not have stable coronary artery disease.

Recommendation:

- Use as directed. The most recent drug label should be consulted for up-to-date guidelines and limitations.

Pharmacogenetics

VERAPAMIL VS. ATENOLOL

INCREASED BENEFIT ON ATENOLOL

INCREASED BENEFIT ON VERAPAMIL

SIMILAR BENEFIT ON VERAPAMIL OR ATENOLOL

Gene Tested - CACNA1C

Clinical Implications:

- Patient's genotype is associated with increased benefit when treated with verapamil instead of atenolol to control blood pressure.
- This result is based on a study of patients with hypertension and stable coronary artery disease and may not apply to patients being treated for other conditions. Benefits included decreased incidence of death, myocardial infarction or stroke.
- See "Condition-Specific Limitations" in the "Risks and Limitations" section of this report for more information.

Recommendation:

- Consider using verapamil if clinically indicated.

Peripheral Arterial Disease / Venous Thrombosis

Pharmacogenetics

CLOPIDOGREL METABOLISM

ULTRARAPID METABOLIZER

EXTENSIVE METABOLIZER

INTERMEDIATE METABOLIZER

POOR METABOLIZER

Genetic Result - CYP2C19 *1/*1

Gene Tested - CYP2C19

Clinical Implications:

- Patient's genotype is associated with normal CYP2C19 enzyme activity, typical plasma concentrations of clopidogrel and its active metabolites, and an effective response to clopidogrel.
- The patient's genotype does not indicate increased risk of stent thrombosis following percutaneous coronary intervention if treated with clopidogrel.
- Other nongenetic factors, such as age and coprescribed medications, may also affect clopidogrel response.
- CYP2C19 genotype and metabolizer status may also affect responses to other drugs.

Recommendation:

- Use as directed. The most recent drug label should be consulted for up-to-date guidelines and limitations.

Pharmacogenetics

ESTROGEN SUPPLEMENTATION

INCREASED RISK OF VENOUS THROMBOSIS

TYPICAL RISK OF VENOUS THROMBOSIS

Genetic Result - Factor V Leiden mutation (0 copies); Prothrombin G20210A mutation (0 copies)

Genes Tested - F2, F5

Clinical Implications:

- Patient does not have the Factor V Leiden or prothrombin G20210A mutation.
- Patient has typical risk of developing venous thrombosis when taking combined hormonal contraceptives or estrogen for hormone replacement therapy.

Recommendation:

- Use as directed. The most recent drug label should be consulted for up-to-date guidelines and limitations.

Health Conditions ✓

PERIPHERAL ARTERIAL DISEASE

INCREASED RISK
ABOVE AVERAGE RISK
AVERAGE RISK

Gene Tested - CHRNA3

Clinical Implications:

- Patient has above average genetic risk of peripheral arterial disease.
- This test outcome was determined using genetic laboratory results in conjunction with the patient's self-reported ethnicity.
- In some populations, genetic differences account for over half of atherosclerosis risk, which causes peripheral arterial disease.

Recommendation:

- Patient education regarding the importance of regular exercise, avoiding exposure to tobacco smoke and the maintenance of a healthy weight and diet may be appropriate to reduce disease risk.

Health Conditions ✓

VENOUS THROMBOSIS

INCREASED RISK
ABOVE AVERAGE RISK
TYPICAL RISK

Genetic Result - Factor V Leiden mutation (0 copies); Prothrombin G20210A mutation (0 copies); MTHFR C677T mutation (1 copy)

Genes Tested - F2, F5, MTHFR

Clinical Implications:

- Patient does not have the Factor V Leiden or prothrombin G20210A mutations that are associated with increased risk of venous thromboembolism (VTE), and does not have the MTHFR C677T genotype associated with increased risk of hyperhomocysteinemia.
- The patient has typical risk of developing venous thromboembolism (VTE). However, this test does not detect other variants that might be associated with increased risk of VTE.

Recommendation:

- The individual's risk for VTE is determined by a complex interaction of genetic, circumstantial and environmental risk factors. Predisposing factors include immobility, surgery, trauma, cancer, hormonal therapy, pregnancy, advanced age and family history.
- This test result should be interpreted together with clinical and family data.

Pharmacogenetics

WARFARIN

SUBSTANTIALLY INCREASED SENSITIVITY

INCREASED SENSITIVITY

TYPICAL SENSITIVITY

Genetic Result - CYP2C9 *1/*1; VKORC1 G/G

Genes Tested - CYP2C9, VKORC1

Clinical Implications:

- Patient's genotype is not associated with increased sensitivity to warfarin.
- In 2010, FDA released a table of dosing recommendations for initiation of warfarin therapy based on vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genotypes. This pharmacogenetics-based dosing table significantly improved accuracy of initial therapeutic dose prediction compared to the traditional strategy of empirically determined dose.
- Appropriate warfarin dose varies greatly between patients; in addition to genetic factors, clinical factors, such as age, sex, body weight, race, comorbidities and interacting medications, also contribute to variability in patient response to a particular warfarin dose.

Recommendation:

- Consideration of VKORC1 and CYP2C9 genotypes, in addition to clinical factors, is recommended for selection of initial dose.
- The most recent warfarin label should be consulted for up-to-date warfarin-dosing guidelines and limitations.

GENOTYPE/HAPLOTYPE DETAIL

PHARMACOGENETICS

This section lists the genetic markers that were tested for Pharmacogenetics. Results are organized by drug response. Each drug response may have two sections, which includes a "Genetic Result" section and an associated table with three columns. "Genetic Result" indicates the haplotype, genotype or presence of a mutation. A genetic result that contains “ND” indicates that a haplotype could not be determined. “Unable To Report” indicates that no result can be provided.

In the tables, results are organized by drug response into three columns:

1. “Gene/Locus” refers to the gene or intergenic region where the marker is located.
2. “Marker” refers to the unique identifier of the tested marker.
3. “Genotype” refers to the combination of nucleotides at a particular marker. The letter(s) on each side of the slash refer(s) to the two copies of the patient’s DNA. "Del" indicates a deletion of the nucleotide(s) in the patient's DNA. A genotype of “- -“ indicates that a result could not be obtained.

BETA-BLOCKERS

GENE/LOCUS	MARKER	GENOTYPE
GRK5	rs17098707	A/A

BETA-BLOCKERS, LVEF RESPONSE

GENE/LOCUS	MARKER	GENOTYPE
ADRB1	rs1801253	C/C

CAFFEINE METABOLISM

Genetic Result: CYP1A2 *1F/*1F

GENE/LOCUS	MARKER	GENOTYPE
CYP1A2	rs762551	A/A

CLOPIDOGREL METABOLISM

Genetic Result: CYP2C19 *1/*1

GENE/LOCUS	MARKER	GENOTYPE
CYP2C19	rs4244285	G/G
CYP2C19	rs4986893	G/G
CYP2C19	rs12248560	C/C
CYP2C19	rs28399504	A/A
CYP2C19	rs41291556	T/T
CYP2C19	rs56337013	C/C
CYP2C19	rs72552267	G/G

ESTROGEN SUPPLEMENTATION

Genetic Result: Factor V Leiden mutation (0 copies); Prothrombin G20210A mutation (0 copies)

GENE/LOCUS	MARKER	GENOTYPE
F2	Prothrombin G20210A	G/G

ESTROGEN SUPPLEMENTATION

Genetic Result: Factor V Leiden mutation (0 copies); Prothrombin G20210A mutation (0 copies)

GENE/LOCUS	MARKER	GENOTYPE
F5	Factor V Leiden	G/G

METOPROLOL METABOLISM

Genetic Result: CYP2D6 *1/*6

GENE/LOCUS	MARKER	GENOTYPE
CYP2D6	rs16947	C/C
CYP2D6	rs769258	G/G
CYP2D6	rs1065852	C/C
CYP2D6	rs1080985	C/C
CYP2D6	rs3892097	G/G
CYP2D6	rs5030655	T/del
CYP2D6	rs5030656	AAG/AAG
CYP2D6	rs5030865	G/G
CYP2D6	rs28371706	C/C
CYP2D6	rs28371725	G/G
CYP2D6	rs35742686	A/A
CYP2D6	rs59421388	G/G

PERINDOPRIL

GENE/LOCUS	MARKER	GENOTYPE
AGTR1	rs5182	C/T
AGTR1	rs275651	A/T
BDKRB1	rs12050217	A/A

SIMVASTATIN-INDUCED MYOPATHY

GENE/LOCUS	MARKER	GENOTYPE
SLCO1B1	rs4149056	T/T

VERAPAMIL AND QTC INTERVAL

GENE/LOCUS	MARKER	GENOTYPE
NOS1AP	rs10494366	T/G

VERAPAMIL VS. ATENOLOL

GENE/LOCUS	MARKER	GENOTYPE
CACNA1C	rs1051375	A/A

WARFARIN

Genetic Result: CYP2C9 *1/*1; VKORC1 G/G

GENE/LOCUS	MARKER	GENOTYPE
CYP2C9	rs1057910	A/A
CYP2C9	rs1799853	C/C
CYP2C9	rs9332131	A/A
VKORC1	rs9923231	G/G

CARRIER STATUS

This section lists the individual mutations that were tested for Carrier Status. Tested mutations are organized by disease and contained in brackets next to their respective genes.

- If the patient carries a tested mutation, it will be highlighted in red in the “Carrier of” section.
- If the patient does not carry a tested mutation, it will be listed in black in the “Not a Carrier of” section.
- If a result could not be obtained for a mutation, it is listed in the “No Data for” section.
- “Pending” indicates that the patient’s test for this disease is still in progress.
- “Unable To Report” indicates that no result can be provided.

Residual risk: since there are many rare mutations, it is possible to carry a mutation that is not included in our test.

SICKLE CELL ANEMIA

Not a Carrier of: HBB [Hemoglobin S]

HEALTH CONDITIONS

This section lists the genetic markers that were tested for Health Conditions. Results are organized by condition into three columns.

1. “Gene/Locus” refers to the gene or intergenic region where the marker is located.
2. “Marker” refers to the unique identifier of the tested marker.
3. “Genotype” refers to the combination of nucleotides at a particular marker. The letter(s) on each side of the slash refer(s) to the two copies of the patient’s DNA. "Del" indicates a deletion of the nucleotide(s) in the patient's DNA. A genotype of “- -“ indicates that a result could not be obtained.

“Unable To Report” indicates that no result can be provided. The strength of scientific evidence for each marker is available in the technical bulletin of the corresponding condition.

APOE, TYPE III HYPERLIPOPROTEINEMIA AND CVD RISK

Genetic Result: APOE ε3/ε3

GENE/LOCUS	MARKER	GENOTYPE
APOE	rs7412	C/C
APOE	rs429358	T/T

ATRIAL FIBRILLATION

GENE/LOCUS	MARKER	GENOTYPE
PITX2	rs2200733	C/T

CORONARY ARTERY DISEASE

GENE/LOCUS	MARKER	GENOTYPE
CDH13	rs8055236	G/G
HNF1A	rs2259816	G/G
Intergenic_10q11	rs501120	T/C
Intergenic_1q41	rs3008621	G/A
Intergenic_2q36	rs2943634	C/C
Intergenic_5q21	rs383830	A/A
Intergenic_8p22	rs17411031	C/C
Intergenic_9p21	rs1333049	G/G
MRAS	rs9818870	C/C
MTHFD1L	rs6922269	A/A
SEZ6L	rs688034	C/C
SMAD3	rs17228212	T/C

HYPERTENSION

GENE/LOCUS	MARKER	GENOTYPE
BCAT1	rs7961152	C/C
PPARGC1A	rs8192678	C/T

MYOCARDIAL INFARCTION

GENE/LOCUS	MARKER	GENOTYPE
CXCL12	rs1746048	C/T
Intergenic_1p13	rs646776	T/T
Intergenic_21q22	rs9982601	C/T
Intergenic_9p21	rs10757278	A/A
MIA3	rs17465637	A/C
OR13G1	rs1151640	T/T
PCSK9	rs11206510	T/T
PHACTR1	rs12526453	C/G
PRR4	rs1376251	C/C
SH2B3	rs3184504	T/C
WDR12	rs6725887	T/T

PERIPHERAL ARTERIAL DISEASE

GENE/LOCUS	MARKER	GENOTYPE
CHRNA3	rs1051730	G/A

VENOUS THROMBOSIS

Genetic Result: Factor V Leiden mutation (0 copies); Prothrombin G20210A mutation (0 copies); MTHFR C677T mutation (1 copy)

GENE/LOCUS	MARKER	GENOTYPE
F2	Prothrombin G20210A	G/G
F5	Factor V Leiden	G/G
MTHFR	rs1801133	C/T

DIET, NUTRITION AND EXERCISE RESPONSES

This section lists the genetic markers that were tested for Diet, Nutrition and Exercise Responses. Results are organized by condition into four columns:

1. "Gene/Locus" refers to the gene or intergenic region where the marker is located.
2. "Marker" refers to the unique identifier of the tested marker.
3. "Genotype" refers to the combination of nucleotides at a particular marker. The letter(s) on each side of the slash refer(s) to the two copies of the patient's DNA. A genotype of "- -" indicates that a result could not be obtained.
4. "Strength" refers to strength of research evidence for the genetic marker and the associated result. Four filled boxes indicate a study of over 2,000 people and at least one study that replicated the results. Three filled boxes indicate a study of over 400 people. Two filled boxes indicate a study of less than 400 people; studies in this category are preliminary but pass Pathway's criteria for statistical significance. One filled box indicates that results are extremely preliminary.

"Unable To Report" indicates that no result can be provided.

GENETIC RISK FOR DECREASED FOLATE

GENE/LOCUS	MARKER	GENOTYPE	STRENGTH
MTHFR	rs1801133	C/T	■■■□

GENETIC RISK FOR DECREASED HDL CHOLESTEROL

GENE/LOCUS	MARKER	GENOTYPE	STRENGTH
ABCA1	rs1883025	C/C	■■■■
ANGPTL4	rs2967605	C/C	■■■■
CETP	rs247616	C/T	■■■■
FADS1	rs174547	T/C	■■■■
GALNT2	rs4846914	A/A	■■■■
HNF4A	rs1800961	C/C	■■■■
KCTD10	rs2338104	C/G	■■■■
LCAT	rs2271293	G/A	■■■■
LIPC	rs10468017	C/C	■■■■
LIPG	rs4939883	T/C	■■■■
LPL	rs12678919	A/A	■■■■
PLTP	rs7679	T/C	■■■■
TTC39B	rs471364	C/C	■■■■
ZNF259	rs964184	G/C	■■■■

GENETIC RISK FOR ELEVATED LDL CHOLESTEROL

GENE/LOCUS	MARKER	GENOTYPE	STRENGTH
ABCG8	rs6544713	C/C	■■■■
APOB	rs515135	C/C	■■■■
CELSR2	rs12740374	G/G	■■■■
HMGCR	rs3846663	C/T	■■■■
HNF1A	rs2650000	C/C	■■■■
intergenic	rs1501908	C/G	■■■■

GENETIC RISK FOR ELEVATED LDL CHOLESTEROL

GENE/LOCUS	MARKER	GENOTYPE	STRENGTH
LDLR	rs6511720	G/G	■■■■
MAFB	rs6102059	C/T	■■■■
NCAN	rs10401969	T/T	■■■■
PCSK9	rs11206510	T/T	■■■■

GENETIC RISK FOR ELEVATED TRIGLYCERIDES

GENE/LOCUS	MARKER	GENOTYPE	STRENGTH
ANGPTL3	rs10889353	C/C	■■■■
APOB	rs7557067	A/A	■■■■
FADS1	rs174547	T/C	■■■■
GCKR	rs1260326	C/C	■■■■
LPL	rs12678919	A/A	■■■■
MLXIPL	rs714052	A/G	■■■■
NCAN	rs17216525	C/C	■■■■
PLTP	rs7679	T/C	■■■■
TRIB1	rs2954029	A/A	■■■■
XKR6	rs7819412	G/A	■■■■
ZNF259	rs964184	G/C	■■■■

See Disclaimer(s) on page 17 of this Report

RESIDUAL RISK AFTER NEGATIVE TEST RESULTS

In the case of a negative test result (not a carrier), there is a residual risk that the patient may have a mutation that is not part of the test panel. Included in the table below are the residual risk estimates for the carrier conditions in the Pathway Genomics carrier status test. Population carrier rate, carrier detection rate and residual risk are shown for conditions and specific populations for which the data is known. For other conditions listed below and populations that are not shown, the prevalence is rare, the mutation detection rate is unknown and residual risk is not calculable.

For individuals with a “NOT A CARRIER” result for a condition for which there is suggestive personal and/or family history, additional genetic testing may be indicated.

For questions regarding the interpretation of residual risk information, please contact Pathway Genomics' genetic counseling department at (877) 505-7374 or counselors@pathway.com.

SICKLE CELL ANEMIA

POPULATION	CARRIER RATE	DETECTION RATE	RESIDUAL RISK
African American	1:15	100.0%	0
Native American	1:150	100.0%	0
Hispanic	1:203	100.0%	0
Arab	1:478	100.0%	0
Caucasian	1:642	100.0%	0
Asian Indian	1:652	100.0%	0
Filipino	1:879	100.0%	0
Asian	1:1315	100.0%	0
Southeast Asian	1:2365	100.0%	0

TEST METHODOLOGY

Genotyping by PCR-based enrichment and next-generation sequencing or by array-based evaluation of multiple molecular probes.

DISCLAIMER

This test was developed and its performance characteristics determined by Ome Ventures Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

If you have any questions about this report or wish to speak with one of Ome Ventures' genetic counselors, please call (877) 505.7374.

RISKS AND LIMITATIONS

Risk of Laboratory Technical Problems or Laboratory Error

The certified testing laboratory has standard and effective procedures in place to protect against technical and operational problems. However, such problems may still occur. The testing laboratory receives samples collected by patients and physicians. Problems in shipping to the laboratory or sample handling can occur, including but not limited to damage to the specimen or related paperwork, mislabeling, and loss or delay of receipt of the specimen. Laboratory problems can occur that might lead to inability to obtain results. Examples include, but are not limited to, sample mislabeling, DNA contamination, un-interpretable results, and human and/or testing system errors. In such cases, the testing laboratory may need to request a new sample. However, upon re-testing, results may still not be obtainable.

As with all medical laboratory testing, there is a small chance that the laboratory could report inaccurate information. For example, the laboratory could report that a given genotype is present when in fact it is not. Any kind of laboratory error may lead to incorrect decisions regarding medical treatment and/or diet and fitness recommendations. If a laboratory error has occurred or is suspected, a health care professional may wish to pursue further evaluation and/or other testing. Further testing may be pursued to verify any results for any reason.

General Limitations

The purpose of this test is to provide information about how a tested individual’s genes may affect carrier status for some inherited diseases, responses to some drugs, risk for specific common health conditions, and/or selected diet, nutrition and/or exercise responses, as well as to learn more about the tested individual’s ancient ancestry, depending upon the specific genetic testing that is ordered by the health care professional. Tested individuals should not make any changes to any medical care (including but not limited to changes to dosage or frequency of medications, diet and exercise regimens, or pregnancy planning) based on genetic testing results without consulting a health care professional.

The science behind the significance or interpretation of certain testing results continues to evolve. Although great strides have been made to advance the potential usefulness of genetic testing, there is still much to be discovered. Genetic testing is based upon information, developments and testing techniques that are known today. Future research may reveal changes in the interpretation of previously obtained genetic testing results. For example, any genetic test is limited by the variants being tested. The interpretation of the significance of some variants may change as more research is done about them. Some variants that are associated with disease, drug response, or diet, nutrition and exercise response may not be tested; possibly these variants have not yet been identified in genetic studies.

Many of the conditions and drug responses that are tested are dependent on genetic factors as well as nongenetic factors such as age, personal health and family health history, diet, and ethnicity. As such, an individual may not exhibit the specific drug response, disease, or diet, nutrition and exercise response consistent with the genetic test results.

Another limitation for some conditions, particularly in the areas of diet and exercise, is that genetic associations have been studied and observed in Caucasian populations only. In this case, the interpretations and recommendations are made in the context of Caucasian studies, but the results may or may not be relevant to tested individuals who are of non-Caucasian or mixed ethnicities.

Based on test results and other medical knowledge of the tested individual, health care professionals might consider additional independent testing, or consult another health care professional or genetic counselor.

Condition-Specific Limitations

The conditions below may not apply to all report types.

- Beta-blockers, LVEF response: whether or not the tested variant modifies the outcomes of beta-blocker therapy is still controversial.
- Verapamil and QTc interval: the association of the tested marker with verapamil-induced QTc interval prolongation has not yet been independently replicated.

See Disclaimer(s) on page 17 of this Report

- Verapamil vs. atenolol: the association of the tested marker with benefits of verapamil versus atenolol has not been independently replicated.

RESULT STATUS DEFINITIONS

Amended 	Test results and/or patient information that have been revised in a way that does not impact the clinical significance of the result(s) and/or patient diagnosis, treatment or management.
Corrected 	Test results and/or patient information that have been revised in a way that may impact the clinical significance of the result(s) and/or patient diagnosis, treatment or management.
Final 	Test results that are available at the time of report issue or have been revised from pending status to final status.
Pending 	Test results that are not available at the time of report issue. All pending results will be specified in the report.

